This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Perspective: Diving into the phase III results from the ANCHOR clinical trials of depemokimab in chronic rhinosinusitis with nasal polyps.

Ticker(s): GSK

Who's the expert?

  • American Board of Allergy & Immunology Certification in Allergy & Immunology
  • treat disorders of the immune system, including food, insect and respiratory allergies, eczema, asthma and immune deficiencies.

  •  Manages about 200 patients with peanut allergy.

Interview Goal
to discuss the current treatment landscape and the potential of depemokimab, an investigational drug being developed by GSK for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.